Related Experiment Videos
Temporins, small antimicrobial peptides with leishmanicidal activity
Maria Luisa Mangoni1, José M Saugar, Maria Dellisanti
1Istituto Pasteur-Fondazione Cenci Bolognetti, Dipartimento di Scienze Biochimiche A. Rossi Fanelli, Azienda Ospedaliera S. Andrea, Italy. marialuisa.mangoni@uniroma1.it
The Journal of Biological Chemistry
|October 30, 2004
Summary
Temporins A and B, frog-derived antimicrobial peptides, show potent activity against Leishmania parasites. Their novel mechanism of membrane permeation offers a promising new avenue for developing antiparasitic drugs.
Area of Science:
- * Antimicrobial peptide research
- * Parasitology
- * Drug discovery
Background:
- * Leishmaniasis is a parasitic disease often opportunistic in immunocompromised individuals.
- * Drug resistance in Leishmania parasites necessitates novel therapeutic agents.
- * Antimicrobial peptides (AMPs) are explored for antiparasitic potential.
Purpose of the Study:
- * To investigate the anti-Leishmania activity of temporins A and B.
- * To characterize the mechanism of action of temporins against Leishmania parasites.
- * To evaluate temporins as potential drug candidates for leishmaniasis treatment.
Main Methods:
- * In vitro assessment of temporin A and B activity against Leishmania.
- * Evaluation of cytolytic effects on human erythrocytes.
- * Analysis of plasma membrane potential, dye influx, ATP levels, and ultrastructural changes via electron microscopy.
Main Results:
- * Temporins A and B exhibit significant leishmanicidal activity at micromolar concentrations.
- * No cytolytic activity was observed against human erythrocytes.
- * Mechanism involves plasma membrane permeation, leading to rapid potential collapse, dye influx, ATP depletion, and membrane damage.
Conclusions:
- * Temporins are short, potent natural peptides with high leishmanicidal activity and low charge.
- * Their serum stability and unique membranolytic mechanism suggest low resistance development potential.
- * Temporins represent promising leads for novel antiparasitic drug design against leishmaniasis.